Today's Pre-Open Movers

Tyme Technologies, Inc. (NASDAQ: TYME) 32.4% HIGHER; announced a potential new approach to treating COVID-19 using a metabolic agent, TYME-19. TYME-19 is a synthetic bile acid, a family of metabolic agents that the Company also uses in its anticancer product, TYME-18. Because of its expertise in metabolic therapies, the Company was able to quickly identify TYME-19 as a potent, well characterized antiviral bile acid and has performed preclinical experiments establishing effectiveness against COVID-19. Bile acids have primarily been used for liver disease; however, they represent a family of critical cellular regulators across cardiovascular, neurologic, and metabolic systems, with some also having antiviral properties.

Anaplan, Inc. (NYSE: PLAN) 28.5% HIGHER; reported Q2 EPS of ($0.04), $0.08 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $106.5 million versus the consensus estimate of $103.45 million. Anaplan, Inc. sees Q3 2021 revenue of $109-110 million, versus the consensus of $108.4 million. Anaplan, Inc. sees FY2021 revenue of $437-439 million, versus the consensus of $433.5 million.

Fluidigm Corporation (Nasdaq: FLDM) 25.4% HIGHER; received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARSCoV2 virus, designed to be run on the Fluidigm® Biomark HD microfluidics platform.Because it is saliva-based, the Advanta Dx SARS-CoV-2 RT-PCR Assay does not require collection via invasive nasopharyngeal swab. The clinical study associated with the EUA submission demonstrated 100 percent agreement between the saliva results from the Advanta Dx SARS-CoV-2 RT-PCR Assay and the results from paired nasopharyngeal samples tested with authorized assays.

Salesforce (NYSE: CRM) 12.7% HIGHER; reported Q2 EPS of $1.44, versus the analyst estimate of $0.67. Revenue for the quarter came in at $5.15 billion versus the consensus estimate of $4.9 billion. Salesforce sees Q3 2021 EPS of $0.73-$0.74, versus the consensus of $0.76. Salesforce sees Q3 2021 revenue of $5.24-5.25 billion, versus the consensus of $5.01 billion. Salesforce sees FY2021 EPS of $3.72-$3.74, versus the consensus of $2.95. Salesforce sees FY2021 revenue of $20.7-20.8 billion, versus the consensus of $20.7 billion.

Geron Corporation (NASDAQ: GERN) 12.5% HIGHER; H.C. Wainwright raised the price target on to $7.00 (from $4.00) while maintaining a Buy rating.